Glenmark gets FDA nod for Voriconazole Tablets

Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets, 50 mg and 200 mg

id-100104706

Voriconazole Tablets are the the therapeutic equivalent of Vfend Tablets

Glenmark Pharmaceuticals (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Voriconazole Tablets, 50 mg and 200mg, the therapeutic equivalent of Vfend Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).

According to IMS Health sales data for the 12 month period ending July 2015, the Vfend market1 achieved annual sales of approximately $91.4 million.

Voriconazole is used in certain types of fungal infections.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X